Claims

1. Use of a molecule comprising at least a sequence of the antibody recognising the antigen and a cell penetrating transport peptide for the preparation of a medicament for the treatment of a disease or health disorder.

2. Use as claimed in claim 1 characterised in that the molecule is a monoclonal antibody to which a cell penetrating transport peptide has been chemically conjugated.

3. Use as claimed in claim 1 characterised in that the molecule is a polyclonal antibody to which a cell penetrating transport peptide has been chemically conjugated.

4. Use as claimed in claims 2 and 3 characterised in that the monoclonal or polyclonal antibodies have been obtained against the GLI1 protein.

5. Use as claimed in claims 2 and 3 characterised in that the monoclonal or polyclonal antibodies have been obtained against the GLI3 protein.

6. Use as claimed in claim 1 characterised in that the molecule comprises a variable sequence of the genetically modified antibody, to which a cell penetrating transport peptide necessary for entering into the cell has been conjugated or has been included in another manner in the sequence thereof.

7. Use as claimed in claim 6 characterised in that the variable sequence of the genetically modified antibody is derived from the human genome.

8. Use as claimed in claim 7 characterised in that the variable sequence of the human genetically modified antibody is obtained by immunisation with an antigen of a transgenic animal having the humanised immune system.

9. Use as claimed in claim 7 characterised in that the variable sequence of the genetically modified antibody is obtained by screening the human antibody expression library with antigen.

10. Use as claimed in claims 7 to 9 characterised in that the GLI1 sequences are used as antigen.

11. Use as claimed in claims 7 to 9 characterised in that the GLI3 sequences are used as antigen when screening the human antibody expression library.

12. Use as claimed in claims 1 to 11 characterised in that the peptide sequence entering into the cell is Transportan TP10.

13. Use as claimed in claims 1 to 11 characterised in that the peptide sequence entering into the cell is a peptide comprising 9 Arginine.

14. Use as claimed in claims 1 to 13 characterised in that any intracellular therapeutic target is used as antigen.

15. A pharmaceutical composition comprising at least one molecule as defined in claims 1 to 14 in association with at least one pharmaceutically acceptable carrier or additive.

16. A method for obtaining a recombinant polypeptide comprising an encoding sequence of the said polypeptide and the sequence of a cell penetrating transport peptide, expression of the recombinant protein in a suitable host organism and purification of the obtained protein.